Financhill
Sell
50

DVA Quote, Financials, Valuation and Earnings

Last price:
$117.39
Seasonality move :
2.87%
Day range:
$116.39 - $118.50
52-week range:
$113.97 - $179.60
Dividend yield:
0%
P/E ratio:
12.18x
P/S ratio:
0.70x
P/B ratio:
95.39x
Volume:
722.4K
Avg. volume:
1.1M
1-year change:
-28.22%
Market cap:
$8.3B
Revenue:
$12.8B
EPS (TTM):
$9.71

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DVA
DaVita, Inc.
$3.4B $3.17 6.42% 3.22% $144.50
DGX
Quest Diagnostics, Inc.
$2.7B $2.50 5.05% 21.08% $197.31
EHC
Encompass Health Corp.
$1.5B $1.19 9.65% 10.17% $140.33
HCSG
Healthcare Services Group, Inc.
$460.4M $0.20 6.72% 43.2% $21.50
SGRY
Surgery Partners, Inc.
$821M $0.16 0.25% 31.79% $25.73
SRXH
SRx Health Solutions, Inc.
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DVA
DaVita, Inc.
$118.25 $144.50 $8.3B 12.18x $0.00 0% 0.70x
DGX
Quest Diagnostics, Inc.
$182.61 $197.31 $20.3B 21.43x $0.80 1.73% 1.90x
EHC
Encompass Health Corp.
$113.04 $140.33 $11.4B 21.36x $0.19 0.62% 1.99x
HCSG
Healthcare Services Group, Inc.
$18.81 $21.50 $1.3B 34.81x $0.00 0% 0.76x
SGRY
Surgery Partners, Inc.
$17.04 $25.73 $2.2B -- $0.00 0% 0.66x
SRXH
SRx Health Solutions, Inc.
$0.39 -- $9.8M 0.14x $0.00 0% 0.07x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DVA
DaVita, Inc.
104.69% 0.569 112.65% 1.05x
DGX
Quest Diagnostics, Inc.
46.79% 0.203 30.05% 0.90x
EHC
Encompass Health Corp.
52.86% 0.219 19.56% 0.97x
HCSG
Healthcare Services Group, Inc.
2.72% 0.178 1.17% 3.40x
SGRY
Surgery Partners, Inc.
69.12% 1.133 83.88% 1.34x
SRXH
SRx Health Solutions, Inc.
13.36% -4.480 -- 1.30x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DVA
DaVita, Inc.
$910M $495.6M 7.72% 61.87% 14.49% $675.5M
DGX
Quest Diagnostics, Inc.
$911M $420M 7.41% 14.33% 14.92% $419M
EHC
Encompass Health Corp.
$299.7M $243.6M 12.69% 24.34% 16.49% $83.7M
HCSG
Healthcare Services Group, Inc.
$102M $45.9M 7.75% 8.02% 9.88% $70M
SGRY
Surgery Partners, Inc.
$155.8M $133.4M 0.32% 0.65% 16.24% $63.8M
SRXH
SRx Health Solutions, Inc.
$2.4M -$1.1M -- -- -15.2% $377K

DaVita, Inc. vs. Competitors

  • Which has Higher Returns DVA or DGX?

    Quest Diagnostics, Inc. has a net margin of 7.02% compared to DaVita, Inc.'s net margin of 9.13%. DaVita, Inc.'s return on equity of 61.87% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    DVA
    DaVita, Inc.
    26.61% $2.04 $14.1B
    DGX
    Quest Diagnostics, Inc.
    32.35% $2.15 $13.8B
  • What do Analysts Say About DVA or DGX?

    DaVita, Inc. has a consensus price target of $144.50, signalling upside risk potential of 22.2%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $197.31 which suggests that it could grow by 8.05%. Given that DaVita, Inc. has higher upside potential than Quest Diagnostics, Inc., analysts believe DaVita, Inc. is more attractive than Quest Diagnostics, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    DVA
    DaVita, Inc.
    1 7 0
    DGX
    Quest Diagnostics, Inc.
    7 9 0
  • Is DVA or DGX More Risky?

    DaVita, Inc. has a beta of 0.996, which suggesting that the stock is 0.439% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.

  • Which is a Better Dividend Stock DVA or DGX?

    DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.73% to investors and pays a quarterly dividend of $0.80 per share. DaVita, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DVA or DGX?

    DaVita, Inc. quarterly revenues are $3.4B, which are larger than Quest Diagnostics, Inc. quarterly revenues of $2.8B. DaVita, Inc.'s net income of $240.2M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, DaVita, Inc.'s price-to-earnings ratio is 12.18x while Quest Diagnostics, Inc.'s PE ratio is 21.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.70x versus 1.90x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DVA
    DaVita, Inc.
    0.70x 12.18x $3.4B $240.2M
    DGX
    Quest Diagnostics, Inc.
    1.90x 21.43x $2.8B $257M
  • Which has Higher Returns DVA or EHC?

    Encompass Health Corp. has a net margin of 7.02% compared to DaVita, Inc.'s net margin of 11.82%. DaVita, Inc.'s return on equity of 61.87% beat Encompass Health Corp.'s return on equity of 24.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    DVA
    DaVita, Inc.
    26.61% $2.04 $14.1B
    EHC
    Encompass Health Corp.
    20.28% $1.24 $5.8B
  • What do Analysts Say About DVA or EHC?

    DaVita, Inc. has a consensus price target of $144.50, signalling upside risk potential of 22.2%. On the other hand Encompass Health Corp. has an analysts' consensus of $140.33 which suggests that it could grow by 24.15%. Given that Encompass Health Corp. has higher upside potential than DaVita, Inc., analysts believe Encompass Health Corp. is more attractive than DaVita, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    DVA
    DaVita, Inc.
    1 7 0
    EHC
    Encompass Health Corp.
    11 0 0
  • Is DVA or EHC More Risky?

    DaVita, Inc. has a beta of 0.996, which suggesting that the stock is 0.439% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.418%.

  • Which is a Better Dividend Stock DVA or EHC?

    DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.62% to investors and pays a quarterly dividend of $0.19 per share. DaVita, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 14.35% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DVA or EHC?

    DaVita, Inc. quarterly revenues are $3.4B, which are larger than Encompass Health Corp. quarterly revenues of $1.5B. DaVita, Inc.'s net income of $240.2M is higher than Encompass Health Corp.'s net income of $174.7M. Notably, DaVita, Inc.'s price-to-earnings ratio is 12.18x while Encompass Health Corp.'s PE ratio is 21.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.70x versus 1.99x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DVA
    DaVita, Inc.
    0.70x 12.18x $3.4B $240.2M
    EHC
    Encompass Health Corp.
    1.99x 21.36x $1.5B $174.7M
  • Which has Higher Returns DVA or HCSG?

    Healthcare Services Group, Inc. has a net margin of 7.02% compared to DaVita, Inc.'s net margin of 9.25%. DaVita, Inc.'s return on equity of 61.87% beat Healthcare Services Group, Inc.'s return on equity of 8.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    DVA
    DaVita, Inc.
    26.61% $2.04 $14.1B
    HCSG
    Healthcare Services Group, Inc.
    21.98% $0.59 $509.9M
  • What do Analysts Say About DVA or HCSG?

    DaVita, Inc. has a consensus price target of $144.50, signalling upside risk potential of 22.2%. On the other hand Healthcare Services Group, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 14.3%. Given that DaVita, Inc. has higher upside potential than Healthcare Services Group, Inc., analysts believe DaVita, Inc. is more attractive than Healthcare Services Group, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    DVA
    DaVita, Inc.
    1 7 0
    HCSG
    Healthcare Services Group, Inc.
    2 3 0
  • Is DVA or HCSG More Risky?

    DaVita, Inc. has a beta of 0.996, which suggesting that the stock is 0.439% less volatile than S&P 500. In comparison Healthcare Services Group, Inc. has a beta of 0.752, suggesting its less volatile than the S&P 500 by 24.779%.

  • Which is a Better Dividend Stock DVA or HCSG?

    DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita, Inc. pays -- of its earnings as a dividend. Healthcare Services Group, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DVA or HCSG?

    DaVita, Inc. quarterly revenues are $3.4B, which are larger than Healthcare Services Group, Inc. quarterly revenues of $464.3M. DaVita, Inc.'s net income of $240.2M is higher than Healthcare Services Group, Inc.'s net income of $43M. Notably, DaVita, Inc.'s price-to-earnings ratio is 12.18x while Healthcare Services Group, Inc.'s PE ratio is 34.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.70x versus 0.76x for Healthcare Services Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DVA
    DaVita, Inc.
    0.70x 12.18x $3.4B $240.2M
    HCSG
    Healthcare Services Group, Inc.
    0.76x 34.81x $464.3M $43M
  • Which has Higher Returns DVA or SGRY?

    Surgery Partners, Inc. has a net margin of 7.02% compared to DaVita, Inc.'s net margin of 3.08%. DaVita, Inc.'s return on equity of 61.87% beat Surgery Partners, Inc.'s return on equity of 0.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    DVA
    DaVita, Inc.
    26.61% $2.04 $14.1B
    SGRY
    Surgery Partners, Inc.
    18.97% -$0.18 $7.4B
  • What do Analysts Say About DVA or SGRY?

    DaVita, Inc. has a consensus price target of $144.50, signalling upside risk potential of 22.2%. On the other hand Surgery Partners, Inc. has an analysts' consensus of $25.73 which suggests that it could grow by 50.98%. Given that Surgery Partners, Inc. has higher upside potential than DaVita, Inc., analysts believe Surgery Partners, Inc. is more attractive than DaVita, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    DVA
    DaVita, Inc.
    1 7 0
    SGRY
    Surgery Partners, Inc.
    8 3 0
  • Is DVA or SGRY More Risky?

    DaVita, Inc. has a beta of 0.996, which suggesting that the stock is 0.439% less volatile than S&P 500. In comparison Surgery Partners, Inc. has a beta of 1.932, suggesting its more volatile than the S&P 500 by 93.198%.

  • Which is a Better Dividend Stock DVA or SGRY?

    DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Surgery Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita, Inc. pays -- of its earnings as a dividend. Surgery Partners, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DVA or SGRY?

    DaVita, Inc. quarterly revenues are $3.4B, which are larger than Surgery Partners, Inc. quarterly revenues of $821.5M. DaVita, Inc.'s net income of $240.2M is higher than Surgery Partners, Inc.'s net income of $25.3M. Notably, DaVita, Inc.'s price-to-earnings ratio is 12.18x while Surgery Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.70x versus 0.66x for Surgery Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DVA
    DaVita, Inc.
    0.70x 12.18x $3.4B $240.2M
    SGRY
    Surgery Partners, Inc.
    0.66x -- $821.5M $25.3M
  • Which has Higher Returns DVA or SRXH?

    SRx Health Solutions, Inc. has a net margin of 7.02% compared to DaVita, Inc.'s net margin of -13.47%. DaVita, Inc.'s return on equity of 61.87% beat SRx Health Solutions, Inc.'s return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    DVA
    DaVita, Inc.
    26.61% $2.04 $14.1B
    SRXH
    SRx Health Solutions, Inc.
    33.29% -$0.07 $9.2M
  • What do Analysts Say About DVA or SRXH?

    DaVita, Inc. has a consensus price target of $144.50, signalling upside risk potential of 22.2%. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that DaVita, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe DaVita, Inc. is more attractive than SRx Health Solutions, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    DVA
    DaVita, Inc.
    1 7 0
    SRXH
    SRx Health Solutions, Inc.
    0 0 0
  • Is DVA or SRXH More Risky?

    DaVita, Inc. has a beta of 0.996, which suggesting that the stock is 0.439% less volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.069%.

  • Which is a Better Dividend Stock DVA or SRXH?

    DaVita, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DaVita, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios DVA or SRXH?

    DaVita, Inc. quarterly revenues are $3.4B, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. DaVita, Inc.'s net income of $240.2M is higher than SRx Health Solutions, Inc.'s net income of -$964K. Notably, DaVita, Inc.'s price-to-earnings ratio is 12.18x while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DaVita, Inc. is 0.70x versus 0.07x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DVA
    DaVita, Inc.
    0.70x 12.18x $3.4B $240.2M
    SRXH
    SRx Health Solutions, Inc.
    0.07x 0.14x $7.2M -$964K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Amazon an AI Stock?
Is Amazon an AI Stock?

With the market starting to look skittish on pure-play AI…

Google Vs NVIDIA Stock: Which Is Best?
Google Vs NVIDIA Stock: Which Is Best?

Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…

How High Could NVIDIA Stock Go?
How High Could NVIDIA Stock Go?

NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…

Stock Ideas

Buy
51
Is NVDA Stock a Buy?

Market Cap: $4.4T
P/E Ratio: 61x

Buy
61
Is AAPL Stock a Buy?

Market Cap: $4.1T
P/E Ratio: 38x

Buy
69
Is GOOG Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 40x

Alerts

Sell
47
PSTG alert for Dec 4

Pure Storage, Inc. [PSTG] is up 5.05% over the past day.

Sell
41
SMX alert for Dec 4

SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.

Sell
43
HY alert for Dec 4

Hyster-Yale, Inc. [HY] is up 1.92% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock